ETUDE VALHEFT valsartan Heart Failure Trial

1. ETUDE VALHEFT(valsartan Heart Failure Trial) This presentation is designed to help trainers conduct a lively and interactive review session with representatives who have successfully completed Module III of the Diovan� VALIANT Learning Program, Introduction to VALIANT. The presentation should be used to reinforce learning through the use of stimulating questions and group problem-solving activities, and is not meant to replace the print and e-based learning materials. The presentation should last approximately one hour, including a suggested break point near the middle. Allow extra time, before the break and at the end of the session, to answer additional questions from the representatives. The representatives, not you, should do most of the talking during this session. You will facilitate the discussion to help the representatives consolidate their knowledge of Module III and determine the relevance of the information to their sales efforts. To lead this session successfully, you will need thorough understanding of the content covered in Module III. For the session itself, a flip chart or white board will be useful for noting valid points made by the representatives. This presentation is designed to help trainers conduct a lively and interactive review session with representatives who have successfully completed Module III of the Diovan� VALIANT Learning Program, Introduction to VALIANT. The presentation should be used to reinforce learning through the use of stimulating questions and group problem-solving activities, and is not meant to replace the print and e-based learning materials. The presentation should last approximately one hour, including a suggested break point near the middle. Allow extra time, before the break and at the end of the session, to answer additional questions from the representatives. The representatives, not you, should do most of the talking during this session. You will facilitate the discussion to help the representatives consolidate their knowledge of Module III and determine the relevance of the information to their sales efforts. To lead this session successfully, you will need thorough understanding of the content covered in Module III. For the session itself, a flip chart or white board will be useful for noting valid points made by the representatives.

2. The session is divided into two discussion topics, which parallel and complement the content organization of Module III: Completed and ongoing Diovan clinical trials The VALIANT trial Allow 30 minutes for discussion of the first discussion point and another 30 minutes, after the break, for discussion of the second discussion point.The session is divided into two discussion topics, which parallel and complement the content organization of Module III: Completed and ongoing Diovan clinical trials The VALIANT trial Allow 30 minutes for discussion of the first discussion point and another 30 minutes, after the break, for discussion of the second discussion point.

3. Valsartan vs placebo : morbi-mortalit� dans l�insuffisance cardiaque 5010 patients insuffisants cardiaques 302 centres de 16 pays 1,9 ans Valsartan 320 mg vs placebo Crit�re principal = mortalit� globale ou mortalit� The session is divided into two discussion topics, which parallel and complement the content organization of Module III: Completed and ongoing Diovan clinical trials The VALIANT trial Allow 30 minutes for discussion of the first discussion point and another 30 minutes, after the break, for discussion of the second discussion point.The session is divided into two discussion topics, which parallel and complement the content organization of Module III: Completed and ongoing Diovan clinical trials The VALIANT trial Allow 30 minutes for discussion of the first discussion point and another 30 minutes, after the break, for discussion of the second discussion point.

4. Mode d�action de Valheft Using the flip chart or white board, create a list of the evidence supporting the use of ACE inhibitors as established by the SAVE, AIRE, and TRACE trials. With the ARB mechanism of action diagram as a reference, have the group describe the scientific basis of support for ARB use. Then transition to a discussion of the clinical information that VALIANT is designed to provide. Using the flip chart or white board, create a list of the evidence supporting the use of ACE inhibitors as established by the SAVE, AIRE, and TRACE trials. With the ARB mechanism of action diagram as a reference, have the group describe the scientific basis of support for ARB use. Then transition to a discussion of the clinical information that VALIANT is designed to provide.

5. Les Sartans dans la protection cardiovasculaire Using the flip chart or white board, create a list of the evidence supporting the use of ACE inhibitors as established by the SAVE, AIRE, and TRACE trials. With the ARB mechanism of action diagram as a reference, have the group describe the scientific basis of support for ARB use. Then transition to a discussion of the clinical information that VALIANT is designed to provide. Using the flip chart or white board, create a list of the evidence supporting the use of ACE inhibitors as established by the SAVE, AIRE, and TRACE trials. With the ARB mechanism of action diagram as a reference, have the group describe the scientific basis of support for ARB use. Then transition to a discussion of the clinical information that VALIANT is designed to provide.

6. B�n�fice significatif sur la morbi-mortalit� Have the group pair off and role play a physician-representative scenario where the representative must describe Val-HeFT design and results.Have the group pair off and role play a physician-representative scenario where the representative must describe Val-HeFT design and results.

7. B�n�fice encore plus important chez les patients non trait�s par un IEC Have the group pair off and role play a physician-representative scenario where the representative must describe Val-HeFT design and results.Have the group pair off and role play a physician-representative scenario where the representative must describe Val-HeFT design and results.

8. Obtention de l�AMM dans l�insuffisance cardiaque Have the group pair off and role play a physician-representative scenario where the representative must describe Val-HeFT design and results.Have the group pair off and role play a physician-representative scenario where the representative must describe Val-HeFT design and results.

9. Autres crit�res VALHEFT Using the flip chart or white board, have the group list secondary and tertiary endpoints and safety and tolerability assessments of VALIANT. Using the flip chart or white board, have the group list secondary and tertiary endpoints and safety and tolerability assessments of VALIANT.

10. MERCI POUR VOTRE ATTENTION